News
-
-
-
COMMUNIQUÉ DE PRESSE
LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
LIR Life Sciences Corp. announces a controlled comparative animal study to evaluate needle-free transdermal delivery of GLP/GIP-based obesity therapies. Study aims to advance transdermal platform and simplify treatment for obesity -
-
-
COMMUNIQUÉ DE PRESSE
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform
LIR Life Sciences Corp. enters R&D Agreement with Neuland Labs for peptide formulations. Neuland Labs to provide services for preclinical evaluation and future collaboration -
-
-
-